Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival.

Liu, Yi; Yin, Xuejiao; Ding, Shengnan; Ge, Jiaying; Ma, Liya; Yang, Min; Luo, Xuxia; Zhong, Chengli; Fang, Sishi; Yao, Qiumei; Zhu, Li; Yu, Wenjuan; Mao, Liping; Wei, Juying; Ye, Xingnong; Zhou, De; Tong, Hongyan; Meng, Haitao; Jin, Jie; You, Liangshun

Liu, Yi; Yin, Xuejiao; Ding, Shengnan; Ge, Jiaying; Ma, Liya; Yang, Min; Luo, Xuxia; Zhong, Chengli; Fang, Sishi; Yao, Qiumei; Zhu, Li; Yu, Wenjuan; Mao, Liping; Wei, Juying; Ye, Xingnong; Zhou, De; Tong, Hongyan; Meng, Haitao; Jin, Jie; You, Liangshun.

Afiliación

Liu Y; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.
Yin X; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, 310003, People's Republic of China.
Ding S; Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, Zhejiang, 310003, People's Republic of China.
Ge J; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.
Ma L; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, 310003, People's Republic of China.
Yang M; Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, Zhejiang, 310003, People's Republic of China.
Luo X; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.
Zhong C; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, 310003, People's Republic of China.
Fang S; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.
Yao Q; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, 310003, People's Republic of China.
Zhu L; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.
Yu W; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, 310003, People's Republic of China.
Mao L; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.
Wei J; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, 310003, People's Republic of China.
Ye X; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.
Zhou; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.
Tong H; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.
Meng H; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.
Jin J; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, 310003, People's Republic of China.
You L; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.

J Hematol Oncol ; 17(1): 60, 2024 Aug 06.

Article en En | MEDLINE | ID: mdl-39107807

ABSTRACT

ABSTRACT

The optimal treatment endpoints and duration of continuous therapy for multicentric Castleman disease (MCD) remain controversial. We retrospectively analyzed data from 123 patients with Human Herpesvirus (HHV)-8 negative MCD. We demonstrated that continuous therapy significantly enhanced progression-free survival (PFS) in patients who achieved an optimal response after initial treatment. These findings underscore the critical role of continuous therapy in HHV-8 negative MCD. Further studies with larger cohorts are required to validate these findings.

Asunto(s)

Enfermedad de Castleman; Herpesvirus Humano 8; Humanos; Enfermedad de Castleman/tratamiento farmacológico; Enfermedad de Castleman/virología; Enfermedad de Castleman/mortalidad; Masculino; Femenino; Estudios Retrospectivos; Persona de Mediana Edad; Adulto; Anciano; Supervivencia sin Progresión; Adulto Joven; Adolescente

Palabras clave

Castleman Disease; Continuous therapy; HHV-8 negative Multicentric Castleman Disease

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Castleman / Herpesvirus Humano 8 Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google